Key Takeaways
- • Kanvas Biosciences secured new funding from the Gates Foundation to develop the first fully synthetic microbiome replacement therapeutic targeting maternal environmental enteric dysfunction (EED) across Southern Asia and Sub-Saharan Africa.
- • The oral product addresses EED, which affects approximately 150 million children globally and is a major contributor to maternal undernutrition, low infant birthweight, and compromised neonatal health outcomes in low-and-middle income settings.
- • Kanvas will leverage its proprietary spatial microbiome imaging platform and vertically integrated anaerobic manufacturing capabilities to design defined, complex multi-strain consortia for scalable, reproducible production of the therapeutic.
- • The company's proprietary AI drug discovery models will accelerate development of the live biotherapeutic product, with clinical evaluation planned in relevant geographical contexts to ensure safety, efficacy, and affordability.
Summary
Kanvas Biosciences, a full-stack spatial biology and microbial therapeutics company headquartered in Princeton, New Jersey, announced a new investment from the Gates Foundation to develop a novel microbiome therapeutic targeting maternal health outcomes in low-resource settings. The funding will support development of the world's first fully synthetic microbiome replacement product designed to treat and prevent environmental enteric dysfunction (EED) in pregnant persons across Southern Asia and Sub-Saharan Africa.
EED is an intestinal condition prevalent in low-and-middle income settings characterized by poor sanitation infrastructure. The condition affects approximately 150 million children worldwide and causes intestinal inflammation, gut lining damage, and compromised intestinal barriers. These pathological changes result in poor nutrient absorption, stunted growth, impaired immune responses, and intergenerational consequences for both maternal and infant health. Maternal EED contributes significantly to undernutrition in pregnant individuals and elevated risk of low infant birthweight and neonatal health complications.
Kanvas will employ its proprietary spatial microbiome imaging platform in conjunction with global metagenomic datasets to identify and isolate microbial strains suitable for therapeutic use. The company will design defined, complex multi-strain consortia informed by its imaging capabilities and translate these into scalable, reproducible products through its vertically integrated, anaerobic manufacturing platform. The development process will be supported by Kanvas' proprietary artificial intelligence drug discovery models, which are engineered to accelerate the development lifecycle of live biotherapeutic products. The company intends to conduct clinical evaluation of the therapeutic candidate in relevant geographical contexts to establish safety, efficacy, and affordability before broader deployment.
EED is an intestinal condition prevalent in low-and-middle income settings characterized by poor sanitation infrastructure. The condition affects approximately 150 million children worldwide and causes intestinal inflammation, gut lining damage, and compromised intestinal barriers. These pathological changes result in poor nutrient absorption, stunted growth, impaired immune responses, and intergenerational consequences for both maternal and infant health. Maternal EED contributes significantly to undernutrition in pregnant individuals and elevated risk of low infant birthweight and neonatal health complications.
Kanvas will employ its proprietary spatial microbiome imaging platform in conjunction with global metagenomic datasets to identify and isolate microbial strains suitable for therapeutic use. The company will design defined, complex multi-strain consortia informed by its imaging capabilities and translate these into scalable, reproducible products through its vertically integrated, anaerobic manufacturing platform. The development process will be supported by Kanvas' proprietary artificial intelligence drug discovery models, which are engineered to accelerate the development lifecycle of live biotherapeutic products. The company intends to conduct clinical evaluation of the therapeutic candidate in relevant geographical contexts to establish safety, efficacy, and affordability before broader deployment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.